Helen Kaul

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial

Peter Borchmann, Justin Ferdinandus, Gundolf Schneider et al. · The Lancet · 2024 · 114 citations · Full text

Medicine, Oncology, Pharmacology +15

Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial

Paul J. Bröckelmann, Ina Bühnen, Karolin Trautmann‐Grill et al. · Journal of Clinical Oncology · 2022 · 92 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma

Jan‐Michel Heger, Laman Mammadova, Julia Mattlener et al. · Journal of Clinical Oncology · 2024 · 40 citations

Medicine, Molecular Medicine, Oncology +17

Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma – Data from the prospective, multicenter phase III HD16 trial

Lutz van Heek, Colin Stuka, Helen Kaul et al. · BMC Cancer · 2022 · 36 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma

Michael Fuchs, Anne Sophie Jacob, Helen Kaul et al. · Leukemia · 2023 · 17 citations · Full text

Medicine, Oncology, Radiation Oncology +15